Statement_of_Work.pdf
PDF 35 KB Posted
- Attached to
- Determining Kinases Inhibited by Malaria Compounds Federal contract opportunity
- Solicitation number
- NIHDA201800525
About this file
Statement of Work
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| Invoice_and_Payment_Provisions.pdf | ||
| FAR_52.212-5.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Version 11-30-2016-1 FAR Part 11—Describing Agency Needs
STATEMENT OF WORK (SERVICES)
(SOW)
GENERAL INFORMATION
Title of Project:
Determining Kinases Inhibited by Malaria Compounds
Statement of Need and Purpose:
NCATS requires contractor results of profiling malaria compounds against a panel of human kinases for 3888 data points at one concentration and 480 IC50 curves.
Background Information and Objective:
Plasmodium falciparum malaria remains a major threat to the public health, especially in tropical and subtropical areas of the world’s poorest countries. The life cycle of Plasmodium falciparum malaria comprises an exogenous sexual phase with multiplication in certain mosquitoes corresponding to the vector of the disease and an endogenous asexual phase with multiplication in the human host. During a blood meal, a malaria-infected female Anopheles mosquito inoculates sporozoites into the human host.
After several asexual cycles in the blood following the hepatic cycle, some merozoites can differentiate into sexual forms known as macro (female) or micro (male) gametocytes. This production of gametocytes from asexual parasites is named gametocytogenesis. Ingestion of these gametocytes by the invertebrate host allows for the following gametocytogenesis process and the continuation of the parasite cycle.
Although the malaria illness is caused by the asexual blood stages, the presence of gametocytes is directly responsible for the infection of the anopheline vector, thus perpetuating the plasmodial cycle.
Thus, identifying drugs which can kill gametocytes is an essential strategy in antimalarial drug development.
Recently we have identified a series of (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-ones with gametocytes killing activity. Since similar compounds were reported as mTOR kinase and human lipid kinases inhibitors, it is important to measure our compounds’ activity against human lipid kinases so that we can develop a strategy to keep the gametocyte killing activity and remove/reduce the human lipid kinase inhibitory activities.
Period of Performance:
Project Initiation Date: receipt of purchase order and the compounds Project Completion Date: 3 weeks after receipt of the compounds
SCOPE OF WORK
General Requirements:
Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to determine the kinases inhibited by malaria compounds as described herein.
Specific Requirements:
Specifically, the contractor shall achieve the scope of the work to obtain kinases’ percent inhibition for 3888 data points at one concentration and 480 IC50 curves of malaria compounds. The data point is the kinase’s percent inhibition. It is generated through the biochemical assay for human kinase inhibition which is usually carried out at 1 uM concentration with n=2 (duplicate). The IC50 curve contains 10 data points with dose response (range from 2.28 nM to 46 uM) which is more labor intense. NCATS has been regularly using both services to measure malaria compounds’ activity against human lipid kinases in previous years.
GOVERNMENT RESPONSIBILITIES
NCATS will provide the compounds to the vendor. Compounds include a series of (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-ones with gametocytes killing activity.
DELIVERY OR DELIVERABLES
Vendor will provide the reports in 3 weeks. The reports shall be provided in Microsoft Excel table format which contains kinases’ percent inhibition for each single data point at one concentration, and 10 data points and its IC50 value for each IC50 curve.
REPORTING REQUIREMENTS
The final report of the project includes kinases’ percent inhibition at one concentration and IC50 values.
OTHER CONSIDERATIONS
Travel:
No travel cost is necessary to complete this Statement of Work nor will be reimbursed by the Government.
Data Rights:
NCATS shall have unlimited rights to and ownership of all deliverables provided under this contract, including reports, recommendations, briefings, work plans and all other deliverables. This includes the deliverables provided under the basic contract and any optional task deliverables exercised by the contracting officer. In addition, it includes any additional deliverables required by contract change. The definition of “unlimited rights” is contained in Federal Acquisition Regulation (FAR) 27.401, “Definitions.”
FAR clause 52.227-14, “Rights in Data-General”, is hereby incorporated by reference and made a part of this contract/order.
Publications and Publicity:
Vendor will not publish any results of the work performed from this contract.
Technical Evaluation / Selection Criteria: (Trade-Off)
The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. Price is an unscored component. Technical Evaluation criteria when combined are significantly more important when compared to price. Each quotation will be evaluated in strict conformity with the evaluation factors, utilizing written critiques.
The evaluation will be based upon the demonstrated capabilities of the prospective contractor in relation to the needs of the project as set forth in the RFQ and will use an adjectival evaluation rating scheme based on the following responses:
Excellent (Risk level: Very low); Good (Risk level: Low); Acceptable (Risk Level: Neutral); Marginal (Risk level: High); Unacceptable (Risk level: Very high).
The following factors shall be used to evaluate offers, listed in order of relative importance:
• Technical Approach o Understanding of the work, including creativity and thoroughness shown in understanding the objectives of the SOW and planned execution of the project.
o Evidence of specific methods and techniques for completing each discrete task, to include such items as quality assurance, customer-service and other performance metrics as detailed in the RFQ.
o Ability to address anticipated potential problem areas, and creativity and feasibility of solutions to problems and future integration of new processes and technology enhancements.
o Degree to which the offerors quote demonstrates an understanding of logistics, schedule, and any other miscellaneous issues in which the Government should be aware.
o Quality and effectiveness of the allocation of personnel and resources.
• Organizational Experience o Evidence that the organization has current capabilities for assuring performance of this requirement.
o Appropriate mix and balance of education and training of team members o The organizations history of successful completion of projects; history of producing high-quality reports and other deliverables; history of staying on schedule and within budget.
o The quality of cooperation between key individuals within your organization and with your clients.
o The organization’s specific past performance on prior similar efforts specified within this SOW; vendor shall highlight and provide reference for previous work and experience with specific laboratory needs similar to this requirement.
| SCOPE OF WORK |
| DELIVERY OR DELIVERABLES |
| Vendor will not publish any results of the work performed from this contract. |
| Technical Evaluation / Selection Criteria: (Trade-Off) |
File details come from the government source that posted it.